A 38-year-old woman presents with a 3-month history of low mood, anhedonia, fatigue and impaired concentration. She has no history of mania or psychosis, and medical workup is normal. She has moderate functional impairment but no current suicidal intent. According to the 2023 CANMAT guideline, which is an appropriate first-line pharmacologic option for major depressive disorder?